Geneseeq, Author at Geneseeq Technology Inc. | A Precision Oncology Company

September 7, 2022

Geneseeq to present five posters at European Society for Medical Oncology 2022

0 Comments6 Minutes

August 3, 2022

GENESEEQ AND COLLABORATORS SHARE NEW FINDINGS AT WORLD CONFERENCE ON LUNG CANCER 2022

0 Comments10 Minutes

July 19, 2022

Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab

0 Comments3 Minutes

July 5, 2022

Geneseeq and collaborators publish new findings from DECIPHER series, exploring single cfDNA feature-based machine learning model for lung cancer early detection

0 Comments3 Minutes

June 13, 2022

Geneseeq Multicancer Early Detection Study Yields Promising Results

0 Comments3 Minutes

May 31, 2022

Geneseeq at ASCO 2022

0 Comments7 Minutes

May 19, 2022

Geneseeq collaborates on another minimal residual disease study in chemoradiotherapy-treated inoperable localized non-small cell lung cancer patients.

0 Comments3 Minutes

April 5, 2022

Geneseeq Presents 9 Posters at AACR 2022

0 Comments12 Minutes

January 4, 2022

Geneseeq’s cancer early detection study series DECIPHER yield another publication in HEPATOLOGY to explore the performance of cfDNA fragmentomics in liver cancer

0 Comments3 Minutes

November 22, 2021

Geneseeq announces new publication utilizing ultradeep sequencing technology Automated TTriple Groom sequencing (ATG-seq) to monitor minimal residual disease in postoperative non-small cell lung cancer

0 Comments3 Minutes